Results showed that application of NS1643 produced a progressive and significant increase in ROS formation within 2h (Figure 7A) in both MDA-MB-231 (Figure 7A) and in HER2+ breast cancer cell lines (Supplementary Figure 3). Here, ERBB2 is linked to breast carcinoma.